BioPharmX Corporation (BPMX)

Home » Stocks » BioPharmX

May 19, 2020 - BPMX merged into TMBR

Stock Price: $0.510 USD 0.000 (0.00%)

Updated May 18, 2020 4:00 PM EDT

• Overview
• Financials

Key Info

Market Cap	9.32M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	1.52M
EPS (ttm)	-0.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Dividend Yield	n/a

Stock Quote

Trading Day	May 18, 2020
Last Price	$0.510
Previous Close	$0.510
Change ($)	0.000
Change (%)	0.00%
Day's Open	-
Day's Range	0.456 - 0.525
Day's Volume	0
52-Week Range	0.250 - 1.180

More Stats

Market Cap	9.32M
Enterprise Value	n/a
Earnings Date (est)	n/a
Ex-Dividend Date	n/a
Shares Outstanding	1.52M
Float	16.07M
EPS (basic)	n/a
EPS (diluted)	-0.75
FCF / Share	n/a

Dividend	n/a
Dividend Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a
Payout Ratio	n/a
Shares Short	91,024
Short Ratio	1.33
Short % of Float	6.80%
Beta	0.63

PE Ratio	n/a
Forward PE	n/a
P/FCF Ratio	n/a
PS Ratio	n/a
PB Ratio	7.90
Revenue	n/a
Operating Income	n/a
Net Income	n/a
Free Cash Flow	n/a

Net Cash	n/a
Net Cash / Share	0.00
Gross Margin	n/a
Operating Margin	n/a
Profit Margin	n/a
FCF Margin	n/a
ROA	-209.33%
ROE	-2,020.23%
ROIC	n/a

Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy	0
Overweight	0
Hold	1
Underweight	0
Sell	0

What these ratings mean

Analyst Consensus: Hold

Price Target

$12.00*

Low

12.0

Current: $0.510

High

12.0

Target: 12.00

*Average 12-month price target from 1 stock analysts.

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name	BioPharmX Corporation
Country	United States
Employees	3
CEO	Steven M. Bosacki

Stock Information

Ticker Symbol	BPMX
Stock Exchange	NYSE American
Sector	Healthcare
Industry	Biotechnology
Unique Identifier	NYSEAMERICAN: BPMX

Description

BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system. Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase IIb clinical trials for the treatment of inflammatory lesions of acne; and BPX04, a topical antibiotic, which is in Phase IIb study for the treatment of inflammatory lesions of papulopustular rosacea. The company serves pharmaceutical companies, physician's practices, dermatologists, and general practitioners. BioPharmX Corporation is headquartered in Campbell, California.